10月5日 - ** 诊断设备供应商 Lumexa Imaging（LMRI.O）的股价在盘前交易中上涨 2%，报 10.6 美元
** 券商Truist Securities首次覆盖 (link)，给予“买入”评级，目标价为18美元
** 该目标价较该股上一交易日收盘价暗示约有74%的上行空间
** 该公司提供诊断成像服务，包括MRI、CT和PET扫描，以及X光、超声和乳腺X光检查服务
** 目前覆盖该股的全部5家券商均给予LMRI“买入”或更高评级；其目标价中位数为17.50美元——LSEG汇编数据
** 截至上一交易日收盘，LMRI股价年内累计下跌44.22%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.